Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC
CME | 1.00 Credit
Program Description
Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on targeted treatments could inform treatment decision-making and help clinicians optimize patient care.
Join a panel of experts from the thoracic oncology team to discuss the clinical relevance of HER2 and HER3 status in the treatment of NSCLC. Panelists will explore the identification of actionable mutations in patients with newly diagnosed NSCLC and review how to select appropriate assays for molecular testing. Experts will also look at the landscape of current and emerging targeted therapies and discuss how to account for individual clinical characteristics and mitigate potential adverse effects.
Intended Audience
Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC.
Commercial Supporters
This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo Inc.